Defining a high mortality risk group among women with primary breast cancer. by Nordén, T. et al.
Br. J. Cancer (1994), 69, 520-524
© Macmillan Press Ltd.,
Defining a high mortality risk group among women with primary breast
cancer
T. Norden', A. Lindgren2, R. Bergstrom3 & L. Holmberg14
Departments of'Surgery and2Pathology, University Hospital, S-751 85 Uppsala; 'Department ofStatistics, Uppsala University,
Uppsala; 4Cancer Epidemiology Unit, University Hospital, S-751 85 Uppsala, Sweden.
Summary Increasing interest has been focused on DNA ploidy, hormone receptor status and tumour size as
prognostic factors in node-negative breast cancer. We analysed these factors in patients operated on for
primary invasive breast cancer between January 1981 and December 1987 in a prospective study of248 women
with no involved axillary nodes and 188 women with positive nodes followed until 15 April 1989. Oestrogen or
progesterone receptor negativity, aneuploidy and tumour diameter exceeding 20 mm were studied as negative
prognostic signs in life table analyses and Cox proportional hazards models of corrected survival. Corrected
survival decreased with increasing number of negative signs. Three to four signs yielded a statistically
significant, two- to threefold higher risk than the others. Survival estimates by life table analyses differed by
20% at 5 years. In the whole group, women with three or four negative factors had a relative risk of dying
from their disease more than twice that of the others. Women with no involved nodes and with three or four
negative factors had a risk ofdying from breast cancer similar to that ofnode-positive women with fewer than
three.
Adjuvant systemic therapy after primary surgery for breast
cancer is of benefit to node-negative as well as node-positive
patients (Early Breast Cancer Triallists' Collaborative Group,
1992). The proportional reduction in recurrence and death
with adjuvant treatment may be of an equal magnitude in
both groups. A recommendation in a Clinical Alert from the
National Cancer Institute (1988) to give adjuvant therapy to
all node-negative patients has met with opposition because of
the limited absolute gain and relatively common side-effects
(DeVita, 1989; McGuire et al., 1989, 1990). Therefore, there
is growing interest in finding prognostic factors that can
select women at high risk for distant metastases and death
from node-negative breast cancer (McGuire et al., 1990).
In studies of prognostic factors, there are methodological
problems. The prognostic information associated with each
factor is determined in mathematical models fitted to the
investigators' own data and with few exceptions (Haybittle et
al., 1982; Todd et al., 1987) not validated in other clinical
settings. This strategy leads to an overestimation of the
predictive value of the factors studied.
Furthermore, the prognostic factors under study have
often been used as guidance for treatment within the studied
cohort, which may confound the results. The results obtained
from selected patient groups (Gelbfish et al., 1988) may not
apply to a wider population.
We wanted to overcome these difficulties by applying a set
of prognostic factors proposed by Sigurdsson et al. (1990) to
a population-based series of breast cancer patients, treated
according to a strict protocol not involving adjuvant systemic
therapy. This model study was chosen as its setting is very
similar to ours with respect to source population and stan-
dards of medical treatment. Measurement of the proposed
prognostic factors is part of the standard examination of
breast cancer tissue.
In our study there was no loss to follow-up. The analysis
included both node-negative and node-positive patients to




We studied all patients from a period when we routinely
sought full information on tumour diameter, axillary lymph
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node involvement, oestrogen and progesterone receptor
status and DNA ploidy. The study period ended when
adjuvant systemic treatment became part of our policy. A
total of 525 women were surgically treated for a primary
invasive breast cancer between January 1981 and December
1987. All were from the primary catchment area of the three
surgical departments that provide all inpatient surgical care
in Uppsala County. For 89 patients treated during this
period, information on these factors was incomplete, as the
analyses were introduced successively into clinical practice.
All such patients, randomly distributed over age and stage,
were excluded. The presence (248 patients) or absence (188
patients) ofinvolved nodes was recorded and data on tumour
characteristics were prospectively entered into a computerised
database.
Treatment
Mastectomy and axillary dissection were routine treatments
at the beginning of the study period for cancers in stages I or
II (UICC). Women with node-positive disease were treated
with adjuvant radiotherapy applied to the axillary, supra-
clavicular and parasternal lymph nodes. Beginning in 1982,
sector resection, with optional radiation of the remaining
breast tissue, was introduced and recommended to most
patients with unifocal tumours in stage I (Holmberg et al.,
1990). Adjuvant systemic therapy was not employed. In
women with stage III or more advanced disease, the treat-
ment was individualised.
Histopathological examination, hormone receptor assays and
DNA measurements
Tumour diameter was measured on the fresh specimen and
the presence or absence of axillary lymph node metastases
was noted.
Cytosol oestrogen receptor (ER) and progesterone receptor
(PR) analyses were made by an isoelectric focusing technique
(Wrange et al., 1978). Tumour specimens were stored at
-70°C for no more than 3 weeks before analysis. Receptor
protein was expressed relative to DNA content, and when
dichotomised into positive and negative a cut-off level of
0.1 fmol per,ug of DNA was used.
The DNA content of tumour cells was analysed by flow
cytometry or single-cell cytometry (Stang et al., 1985). No
distinction has been made between data acquired by the two
methods. The classification described by Auer et al. (1980)
was used, in which types I and II represent diploid tumours
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without or with a small percentage of cells in S-phase respec-
tively. Types III and IV represent aneuploid tumours.
Follow-up
The national register on causes of death contains information
on the date and cause of death of all deceased Swedish
citizens. The information on cause of death is broken down
into 'cause of death' and 'contributing factors'. Breast
cancer, when encountered in either group, was considered to
be an event in calculating the corrected survival rates. Deaths
from other causes or survivals to the end of follow-up were
treated as censored observations. The register was updated
until December 1986 at the time of this follow-up. The cause
of death of more recently deceased subjects was ascertained
by queries to the local civic registration authorities. By this
means the follow-up period was brought up to April 1989.
The median follow-up time was 5 years.
Statistical methods
In the uni- and multivariate analyses of corrected survival
rates, the Cox proportional hazards model was used. (Cox,
1972). The basic model assumes that the hazard ('instan-
taneous death rate') h(t x) can be written:
h(t x) = ho(t) exp (fil xl + . . . Pk XJ),
where ho(t) is a baseline hazard function for individuals with
all the explanatory variables xl ... xk equal to 0. The
parameter PI represents the change in the logarithm of the
hazard function as the variable xl changes by one unit, given
that the other variables remain unchanged. A positive value
of PI implies an increase in the hazard function - i.e. poorer
survival prospects. The effect of the hazard associated with
the variable xl is exp (PI), which we call the relative hazard
(RH). For variables in categorical form, as in this study
(oestrogen or progesterone receptor negativity, a tumour
diameter of more than 20 mm or DNA aneuploidy), the RH
shows the hazard for the individual in a certain category, as
compared with the reference category (ER or PR positivity, a
diameter of 20 mm or less or diploid tumour).
The effect on survival associated with combinations of risk
factors was analysed in two different ways in addition to the
direct proportional hazards estimation. In the first type of
analysis the number of poor prognostic signs was recorded.
This produced a variable with five possible values (0, 1, 2, 3
and 4). This modelling assumes that equal risks are
associated with each variable. In further modelling, risk
variables were constructed using the parameters obtained in
the proportional hazards estimation. This allowed different
risks for different basic variables. The weights actually used
are shown in the Results section.
present. In terms of attributable risk those with four
indicators shows an excess risk of 36% [95% confidence
interval (CI) 14-58%], at 5 years, of dying from breast
cancer compared with those with none of the indicators
present. The excess early mortality associated with four risk
factors is illustrated in Figure 1. The corresponding analysis
in the node-positive group shows decreasing survival with
increasing number of risk factors, in much the same way as
among node-negative women, though at a somewhat less
favourable level overall. The 5-year life table estimate among
node-positive women with four risk factors indicates a 53%
attributable risk of dying from breast cancer compared with
those with none.
Figure 2 shows the life table estimates for four different
subsets of patients: node-negative patients with two or fewer
indicators vs those with three or more, and the corresponding
subgrouping for the node-positive patients. The graphs
shown for the node-negative patients with three or more
poor prognostic indicators is very similar to the graph for the
women with two or fewer indicators in the node-positive
patient group. The difference between the life table estimates
at 5 years for the two different groups of node-negative
patients was 20% (95% confidence interval 9-31%).
Coxproportional hazards models
Table III shows the results from multivariate models for
prognosis, when patients were classified according to number
of the factors hypothesised to be detrimental. In node-
negative patients, we found a relative hazard of 2 (95%
confidence interval 1.9-2.1) for 2-3 risk factors present and
a relative hazard of about 6 when four were present. How-
ever, none of the relative hazard estimates was statistically
different from 1.
In a further model derived from data on all patients (Table
III), women with negative nodes and none of the indicators
present formed the reference group. In this model, the same
pattern was seen with a statistically significant value (RH 6.4;
95% CI 1.5-3.3) for node-negative patients with four of the
indicators present. In this model, a relative hazard of 3.4 was
associated with node positivity, i.e. the RH of a node-positive
woman is obtained by multiplying the risk estimate for any
given number of risk factors in node-negative women by a
factor of 3.4.
When node-negative patients were divided in two strata
with 0-2 or 3-4 prognostic indicators present (Table IV),
the difference between the subgroups was clearly statistically
significant at a relative hazard of 2.4 in a multivariate model.
In a corresponding model utilising data on all patients (Table
IV), the risk estimate with 3-4 indicators present was 2.9 for
node-negative women and the relative hazard for node-
positive women was virtually unchanged (3.3) as compared
with the previous models.
Results
The distribution of receptor status, aneuploidy and tumour
diameter is displayed in Table I for both node-negative and
node-positive patients. As expected, the mean tumour
diameter, as well as the proportion of tumours exceeding
20mm, was larger among node-positive patients. The pro-
portion of aneuploid tumours was slightly greater in the
node-positive group.
The number and pecentages of women with none or up to
four of the poor prognostic signs present are shown in Table
II. Of the node-negative patients 39.8% had three or more of
the indicators of poor prognosis; the corresponding propor-
tion among node-positive patients was 49.5%.
Life table analyses
Life table analysis on both node-negative and node-positive
patients stratified according to the number of prognostic
factors present is shown in Table II. There is a constantly
worsening prognosis with increasing number of risk factors
Table I Patient and tumour characteristics: distribution ofproposed
risk factors in node-negative and node-positive patients
Node negative Node positive
(n =248) (n = 188)
Age (years) [mean (s.d.)] 63.8 (14.7) 61.5 (14.2)
Tumour diameter (mm) 21.0 (15.7) 27.7 (16.5)
[mean (s.d.)]
Premenopausal [no. (%)] 52 (21.0) 47 (25.0)
Risk factors
Oestrogen receptor 86 (34.7) 78 (41.5)
negative [no. (%)]
Progesterone receptor 115 (46.4) 96 (51.5)
negativea [no. (%)]
Tumour diameter >20mm 104 (41.9) 127 (67.6)
[no. (%)]
DNA aneuploidyb [no. (%)] 168 (67.7) 149 (79.3)
a.0.1 fmol per1tg of DNA. bGroup III or IV according to Auer
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Table H Corrected survival by number of risk factors presenta. Five-year survival estimates with 95% confidence
interval by the actuarial method, node-negative patients and node-positive patients
Node negative Node positive
Number of risk Five-year Five-year
factors present n (%) survival 95% CI n (%) survival 95% CI
0 23 (9.3) 1.00 - 8 (4.3) 0.87 0.63-1.11
1 68 (27.4) 0.94 0.86-1.02 35 (18.6) 0.85 0.71-0.99
2 83 (33.5) 0.87 0.77-0.97 52 (27.7) 0.73 0.55-0.91
3 44 (17.7) 0.88 0.76-1.00 53 (28.2) 0.52 0.34-0.70
4 30 (12.1) 0.65 0.43-0.87 40 (21.3) 0.34 0.16-0.52
248 (100) 188 (100)
aRisk factors: tumour diameter >20mm, oestrogen receptor negativity ( 0.1 fmol per pg of DNA),
progesterone receptor negativity (,0.1 fmol per iLg of DNA), DNA aneuploidy (as Table I).
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Figure 1 Corrected survival by number or risk factors. Life table
analysis. Node-negative patients only. A, no risk factors; 0, one
risk factor; A, two risk factors; 0, three risk factors; 0, four
risk factors. Risk factors: as Table II.
We also evaluated each one of the prognostic indicators
separately (Table V). In a model with node-negative patients
only, the risk estimate for aneuploid tumours was the highest
(RH = 6.2) and the only one statistically significant. In the
model including all patients, the increased risks associated
with both progesterone receptor negativity and a tumour
diameter exceeding 20 mm were found to be statistically
significant. The risk estimate for aneuploid tumours was
smaller than in the first model but still statistically significant.
The risk estimate for node positivity remained virtually the
same as above.
In further analyses, interaction terms between nodal status
and risk factors studied (individually or dichotomised as in
Table III) were formed. The estimates for the interaction
terms were small and statistically far from significant. Thus,
there was no indication that the prognostic information from
these factors varied according to nodal status.
Risk index
Taking prognostic factors only as present or absent means
that we assume that the risks associated with each factor are
equal. As shown in Table V, this is not the case. To construct
a better risk index, we used the P-parameters obtained for PR
(progesterone receptor negativity), ER (oestrogen receptor
negativity), AU (aneuploid tumour) and DI (tumour
diameter exceeding 20 mm) in the Cox analysis:
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Figure 2 Corrected survival by number or risk factors. Life table
analysis. Node-negative patients and node-positive patients,
dichotomised between 0-2 risk factors and 3-4 risk factors.
Node-negative: A, 0-2 risk factors; 0, 3-4 risk factors. Node-
positive: *, 0-2 risk factors; 0, 3-4 risk factors. Risk factors:
as Table II.
The model, assuming the effect of all the four variables to be
equal, is inferior to this index. However, the index is not a
major improvement compared with the model shown in
Table III. Using index 1, we obtain 16 different possible
values, the largest being 2.62 when all risk factors are present
(0.60 + 0.18 + 0.94 + 0.90). Having four risk factors thus
implies a relative hazard of 13.7 compared with the most
favourable group. A grouping based on quartiles of the index
value (Table VI) confirms that this more complicated model
is not markedly superior. The relative hazard of oestrogen
receptor negativity (Table V) was not significantly different
from 1. So, the index 1 model can be simplified by deleting
this variable:
Index 2 = 0.65 PR + 0.97 AU + 0.94 DI.
This approach, which yields only eight possible values, is
about equal to the index based on all four variables (Table
VI).
Discussion
About one-third of the patients with stage I breast cancer in
this study - with three or more negative prognostic factors
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Table III Multivariate Cox proportional hazards models of corrected survival
by number (0-4) of risk factors presente in any combination. Relative hazard
estimates (RH) with 95% confidence interval (CI)
Node negative All patients (NO and N+)
Number of risk Number of risk
factors present RH 95% CI factors present RH 95% CI
0 Ref. 0 Ref.
1 0.7 0.1- 7.3 1 1.0 0.2- 4.5
2 2.1 0.3-16.7 2 2.1 0.5- 9.3
3 1.9 0.2- 2.8 3 3.0 0.7-12.7
4 5.9 0.8-46.4 4 6.4 1.5-26.6
N + 3.4 2.1- 5.4
'Risk factors: as Table II.
Table IV Multivariate Cox proportional hazards models of corrected survival
by number of risk factorsa present. Dichotomised: 0-2 and 3-4. Relative hazard
estimates (RH) with 95% confidence interval (CI)
Node negative All patients (NO and N+)
Number of risk Number of risk
factors present RH 95% CI factors present RH 95% CI
0-2 Ref. 0-2 Ref.
3-4 2.4 1.1-5.3 3-4 2.9 1.8-4.5
N+ 3.3 2.1-5.3
aRisk factors: as Table II.
Table V Multivariate Cox proportional hazards models of
corrected survival by individual risk factors. Relative hazard
estimates (RH) with 95% confidence interval (CI). Models utilising
data on node-negative patients and on all patients
All patients
Node negative (NO and N+)
Risk factors RH 95% CI RH 95% CI
Progesterone 0.9 0.4- 2.1 1.8 1.1-2.9
receptor negativitya
Oestrogen receptor 2.1 0.9- 5.0 1.2 0.8-1.9
negativitya
DNA aneuploidyb 6.2 1.5-26.3 2.6 1.3-5.2
Tumour diameter 1.6 0.7- 3.6 2.5 1.4-4.3
>20 mm
Node positive - 3.2 2.0-5.2
1' K0.1 fmol per jug of DNA. bAs Table I.
Table Vt Multivariate Cox proportional hazards models of
corrected survival. Improved indices models. Relative hazard (RH)
estimates for each quartile of index values, with 95% confidence
intervals (CI)
Model I Model II
Index quartile Index 1' 95% CI Index 2b 95% CI
First Ref. Ref.
Second 1.1 0.4- 2.9 1.0 0.4- 2.9
Third 2.1 0.9- 4.9 2.2 1.0- 5.2
Fourth 5.3 2.4-11.7 5.5 2.5-12.4
Node positive 3.2 2.0- 5.2 3.3 2.1- 5.3
1Index 1 = 0.60 PR + 0.18 ER + 0.94 AU + 0.90 DI. bIndex
2 = 0.65 PR + 0.97 AU + 0.94 DI. Abbreviations: PR, progesterone
receptor negative; ER, oestrogen receptor negative; AU, aneuploid
tumour; DI, tumour diameter exceeding 20 mm.
prognosis as those doing best among node-positive women.
These findings are similar to those obtained in our model
study (Sigurdsson et al., 1990) and by others (Clark et al.,
1989).
The prognostic factors were not different in node-positive
and node-negative patients. One, therefore, might lose stati-
stical power unecessarily by restricting prognostic studies to
node-negative patients.
The combination of factors studied was not strictly the
best predictor of outcome in our patients. However, these
easily measured clinical parameters (tumour diameter, DNA
ploidy and oestrogen and progesterone receptor status) could
clearly distinguish groups with clinically meaningful
differences in prognosis even in rather simple statistical
models. More complicated models with weighted indices were
only marginally better. Three of our four variables are con-
tinuous by nature and their dichotomised form need not be
optimal from a statistical point of view. Use of the variables
in continuous form or in categorised form determined by
statistical modelling, rather than by clinical conventions,
could lead to a more efficient use of available data. A draw-
back with approaches of this kind is that they are more
complicated to construct, use and understand.
It is not likely that our results are due to bias. The patients
were not subjected to any systemic adjuvant therapy guided
by the prognostic factors studied. Even if surgery and
radiotherapy differed according to tumour size and nodal
status, the degree of confounding due to treatment effects
should be negligible. The external validity is probably high,
since the cohort is population based. The patients excluded
from the beginning of the study period when not all analyses
were routinely performed should not render the analyses
biased, since there were no systematic exclusion criteria, but
rather a random inclusion of patients as the methods were
successively available. There was no loss to follow-up.
Although we have been able to confirm the possibility of
defining a subpopulation of stage I patients with less
favourable prognosis, we do not know whether these women
are those who will benefit from adjuvant systemic treatment.
For example, receptor negativity would imply a lower sen-
sitivity to hormonal treatment, at least concerning recur-
rence, as shown in the metanalysis by the Early Breast
Cancer Triallists' Collaborative Group (1992). On the other
hand, a group of women with few or no poor prognostic
signs have a very good prognosis. Even if adjuvant systemic
therapy were to be effective in those patients who would
otherwise have a less favourable outcome, treating all
patients with node-negative breast cancer seems to be of
doubtful cost-effectiveness (Hillner & Smith, 1992).
There are also both high- and low-risk patients among
node-positive patients. However, in this 'low-risk' group the
mere presence of axillary lymph node metastases implies a
relative hazard of dying from breast cancer exceeding 3,
confirming the theory that when axillary lymph node meta-524 T. NORDEN et al.
stases have occurred the tumour has been present long
enough to give rise to viable distant metastases in a large
number of cases.
The event of axillary metastases may be seen as a function
of tumour growth time. Tumour size reflects the same dimen-
sion. However, there were no signs of interaction between
nodal status and receptor status or DNA ploidy. Receptor
status and DNA ploidy can thus be interpreted to reflect a
dimension of metastatic capacity independent of tumour
burden, as well as of the time the tumour has been present.
These factors might therefore be used in studies of whether
early diagnosis has an impact on prognosis mainly by detec-
tion in a phase of less tumour burden and/or by capturing
tumours of a less aggressive nature, as has been proposed
(Duffy et al., 1992).
This study provides further evidence that a high-risk group
among node-negative patients can be distinguished by means
of parameters that are today easily measured. It may also be
that nuclear grading can replace the more cumbersome DNA
measurements (Fisher et al., 1990). It is, however, far from
clear how these patients respond to systemic treatment. Ran-
domised studies will evaluate whether chemotherapy or hor-
monal manipulation in an adjuvant setting in high-risk
patients will be cost-effective. The question of malignancy
progression during the early growth phase needs to be ad-
dressed in further studies on screening detected breast
cancers.
This study was supported by grants from the Swedish Cancer
Society.
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